Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vincristine, bleomycin, mitomycin C, cisplatin combination chemotherapy as additive treatment to radiotherapy in poor risk patients with squamous cell carcinoma of the uterine cervix.
Vermorken JB, vd Burg ME, Subandono AJ, Mangioni C, De Oliveira CF, Zola P, van Oosterom AT, Pecorelli S, van Lindert AC. Vermorken JB, et al. Among authors: van lindert ac, van oosterom at. Prog Clin Biol Res. 1985;201:225-37. Prog Clin Biol Res. 1985. PMID: 2419917 No abstract available.
Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study.
Wagenaar HC, Pecorelli S, Mangioni C, van der Burg ME, Rotmensz N, Anastasopoulou A, Zola P, Veenhof CH, Lacave AJ, Neijt JP, van Oosterom AT, Einhorn N, Vermorken JB. Wagenaar HC, et al. Among authors: van oosterom at, van der burg me. Eur J Cancer. 2001 Sep;37(13):1624-8. doi: 10.1016/s0959-8049(01)00178-2. Eur J Cancer. 2001. PMID: 11527687 Clinical Trial.
Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix.
Vermorken JB, Mangioni C, Pecorelli S, Van Der Burg ME, Van Oosterom AT, Ten Bokkel Huinink WW, Rotmensz N, Dalesio O. Vermorken JB, et al. Among authors: van oosterom at, van der burg me. Int J Gynecol Cancer. 2000 Sep;10(5):358-365. doi: 10.1046/j.1525-1438.2000.010005358.x. Int J Gynecol Cancer. 2000. PMID: 11240699
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Vermorken JB, van Lindert AC, Heintz AP, Aartsen E, van Lent M, et al. Neijt JP, et al. Among authors: van lindert ac, van lent m, van oosterom at, van der burg me. Eur J Cancer. 1991;27(11):1367-72. doi: 10.1016/0277-5379(91)90011-2. Eur J Cancer. 1991. PMID: 1835850 Clinical Trial.
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Vriesendorp R, Kooyman CD, van Lindert AC, Hamerlynck JV, van Lent M, van Houwelingen JC, et al. Neijt JP, et al. Among authors: van lindert ac, van lent m, van oosterom at, van houwelingen jc, van der burg me. Lancet. 1984 Sep 15;2(8403):594-600. doi: 10.1016/s0140-6736(84)90594-4. Lancet. 1984. PMID: 6147640 Clinical Trial.
367 results